case_images: PMC7378529_01
case_images: Baseline computed tomography (CT) showing a lung mass in the left lower lobe pulmonary window (A) and mediastinal window (C), and an enlarged left lower paratracheal (4L) lymph node (E); CT images after two cycles of four drug combination therapy showing partial response in the pulmonary window (B) and mediastinal window (D), and a significantly reduction in the 4L lymph node (F).
case_images: fonc-10-01145-g0001.jpg
case_images: PMC7378529_01_fonc-10-01145-g0001.jpg
case_images: F1
case_images: Computed tomography (CT) revealed a lung mass in the left lower lobe (Figures 1A,C) and multiple hilar and mediastinal lymph nodes (Figure 1E). After two cycles of neoadjuvant therapy, the Positron emission tomography/Computed tomography (PET/CT) revealed that the tumor was reduced from 4.6 x 2.0 cm to 1.4 x 1.1 cm (Figures 1B,D) with a normal standard uptake value (SUV), and there were no enlarged mediastinal or hilar lymph nodes (Figure 1F).
case_images: The HE showed an increase in the number of residue cancer cells, but fibrosis still predominated in 20x (A) and in 40x (B).
case_images: fonc-10-01145-g0002.jpg
case_images: PMC7378529_01_fonc-10-01145-g0002.jpg
case_images: F2
case_images: It was characterized by an increase in the number of residue cancer cells, but fibrosis still predominated (Figures 2A,B).
case_images: The timeline showing the relevant data of treatment.
case_images: fonc-10-01145-g0003.jpg
case_images: PMC7378529_01_fonc-10-01145-g0003.jpg
case_images: F3
case_images: The timeline of treatment with relevant data of care was shown in Figure 3.